Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Haemonetics said it completed its 4-year long-range plan, achieving almost all targets, including 10% revenue growth versus a high-single-digit goal, mid-20s earnings growth versus a mid-teens goal, and more than $650 million in free cash flow. The company fell slightly short on margin expansion, with operating margin at 18%. The commentary is constructive but largely retrospective, with limited immediate market impact.

Analysis

HAE looks like a classic post-transition compounding story where the market may still be pricing the company as if the hard part is behind it. The key second-order effect is not just margin recovery, but operating leverage on a cleaner revenue base: once the large-customer drag and pandemic normalization roll off, incremental growth should translate into disproportionately stronger EPS and cash conversion because a lot of the prior cost structure has already been rationalized.

What matters now is whether management can prove the next leg is durable rather than cyclical. If free cash flow remains above the recent run-rate for another 2-3 quarters, the market will likely re-rate HAE from a “turnaround execution” name to a “self-funded compounder,” which typically supports multiple expansion even without aggressive top-line acceleration. The risk is that investors have already underwritten too much of the easy margin recovery, so any pause in gross margin improvement could cap upside quickly.

The competitive implication is subtle: a company that has stabilized after a customer transition often becomes more dangerous, not less, because it can reinvest in service, pricing, and account management while peers are still fighting their own operational issues. That can pressure smaller competitors or contract manufacturers that relied on HAE being distracted. Conversely, if healthcare capex or procedure volumes soften, HAE’s improved earnings quality will not protect it from a de-rating, since the multiple is likely more sensitive to growth confidence than to near-term absolute profitability.

The contrarian angle is that the market may be too focused on the fact they nearly hit the old plan and not enough on what that implies for the next plan. A company that beat its own aspirational growth and cash targets by that margin usually has more internal confidence than external investors assign, and that often shows up in quiet repurchases, selective investment, and better-than-feared guidance cadence over the next 6-12 months. The setup is constructive, but the trade should be built around confirmation, not anticipation, because the stock can still chop if guidance remains framed as “post-LRP normalization” rather than a new growth regime.

Key Decisions for Investors

• Go long HAE on a 3-6 month horizon, but size as a confirmation trade; add only if the next quarter shows sustained FCF conversion and no re-acceleration in customer-transition noise. Upside is multiple expansion if the market re-rates it from turnaround to compounder; downside is limited if execution holds, but the stock can stagnate if investors see guidance as peak-normalization.
• Consider a call spread in HAE expiring 6-9 months out to express upside from a re-rating without overpaying for volatility. This is attractive if implieds remain anchored to historical execution-risk discount rather than the improving cash-flow profile.
• Pair HAE long against a higher-quality healthcare-services or devices peer short if you want to isolate execution re-rating rather than sector beta. The thesis is that HAE’s delta to operational improvement is underappreciated, while the short leg should be a name with less margin expansion optionality.
• If the next earnings print shows margin plateauing, reduce or exit quickly; the risk/reward deteriorates if the market starts treating recent performance as fully baked. This is a 1-2 quarter catalyst-driven position, not a long-duration secular call until the company proves the next LRP.